37
Participants
Start Date
October 16, 2019
Primary Completion Date
March 26, 2021
Study Completion Date
June 25, 2021
SOF/VEL
Tablets administered orally once daily
Nippon Medical School Hospital, Inzai-shi
Matsuyama Red Cross Hospital, Matsuyama
Chiba University Hospital, Chiba
Fukui-ken Saiseikai Hospital, Fukui
Japanese Red Cross Fukuoka Hospital, Fukuoka
Hiroshima University Hospital Institution Review Board, Hiroshima
Iizuka Hospital, Iizuka
Saitama Medical University Hospital, Iruma
Juntendo University Shizuoka Hospital, Izunokuni
Nara Medical University Hospital, Kashihara-shi
Toranomon Hospital Kajigaya, Kawasaki-shi
Kumamoto Shinto General Hospital, Kumamoto
Kurme University Hospital, Kurume-shi
Japanese Red Cross Musashino Hospital, Musashino
Hyogo College of Medicine Hospital Institutional Review Board, Nishinomiya
National Hospital Organization Nagasaki Medical Center, Omura-shi
Osaka Red Cross Hospital, Osaka
Osaka City University Hospital, Osaka
Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital, Sapporo
Osaka University Hospital, Suita-shi
Kagawa Prefectural Central Hospital, Takamatsu
Toranomon Hospital, Tokyo
Lead Sponsor
Gilead Sciences
INDUSTRY